GFM
ABUS icon

GF Fund Management’s Arbutus Biopharma ABUS Stock Holding History

GF Fund Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.5K Sell
4,071
-229
-5% -$1.01K ﹤0.01% 485
2026
Q1 		$19.4K Buy
4,300
+522
+14% +$2.28K ﹤0.01% 503
2025
Q4 		$18.2K Sell
3,778
-346
-8% -$1.56K ﹤0.01% 516
2025
Q3 		$18.7K Sell
4,124
-728
-15% -$2.67K ﹤0.01% 496
2025
Q2 		$15K Hold
4,852
– – ﹤0.01% 526
2025
Q1 		$16.9K Buy
4,852
+873
+22% +$2.91K ﹤0.01% 519
2024
Q4 		$13K Buy
+3,979
New +$14.6K ﹤0.01% 514

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GF Fund Management's ABUS Position: Q2 2026 in Review

GF Fund Management reduced its Arbutus Biopharma (ABUS) stake by 5.3% in Q2 2026, selling an estimated $1.01K and leaving 4,071 shares worth $19.5K. The position accounts for ﹤0.01% of the portfolio, ranked #485.

GF Fund Management first reported a position in ABUS in Q4 2024 and has held it in 7 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • GF Fund Management held 4,071 shares of Arbutus Biopharma worth $19.5K as of Q2 2026.
  • GF Fund Management sold 229 Arbutus Biopharma shares in Q2 2026, an estimated $1.01K.
  • Arbutus Biopharma made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #485 holding.
  • GF Fund Management first reported a position in Arbutus Biopharma in Q4 2024 and has held it in 7 quarters since.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.